Key result
Alirocumab cuts recurrent ischemic events versus placebo in post-ACS patients on high-intensity statins.
Why the study?
Does alirocumab reduce recurrent ischemic cardiovascular events in patients with previous acute coronary syndrome receiving high-intensity statin therapy?
Does alirocumab reduce recurrent ischemic cardiovascular events in patients with previous acute coronary syndrome receiving high-intensity statin therapy?
Alirocumab reduces the risk of recurrent ischemic cardiovascular events in patients with a history of acute coronary syndrome on background high-intensity statin therapy.
Supports alirocumab addition in very high-risk post-ACS patients; confirms cardiovascular benefit of further LDL lowering beyond high-intensity statins.
Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY OUTCOMES ClinicalTrials.gov number, NCT01663402 .).
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (2018) studied this question. Alirocumab reduced the risk of recurrent ischemic cardiovascular events compared to placebo in patients on high-intensity statin therapy post-acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: